EIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4898-4908

  Yang, Jianling ^a   Wang, Jun ^a   Chen, Ke ^a   Guo, Guijie ^a   Xi, Ruijiao ^a   Rothman, Paul B ^d,g   Whitten, Douglas ^e   Zhang, Lianfeng ^b   Huang, Shile ^f   Chen, Ji Long ^a,c  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b BEIJING HOSPITAL   (China)

^c FUJIAN AGRICULTURE AND FORESTRY UNIVERSITY   (China)

^d UNIVERSITY OF IOWA   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; INITIATION FACTOR 4B; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; SERINE; SMI 4A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; GENE FUNCTION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SOLID TUMOR; TRANSGENIC MOUSE; TUMOR ENGRAFTMENT; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EUKARYOTIC INITIATION FACTORS; GENE KNOCKDOWN TECHNIQUES; GENES, ABL; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICE; MICE, TRANSGENIC; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-PIM-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881415177     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4277     Document Type: Article

References (50)

1. Rosenberg N, Witte ON. The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res 1988;35:39-81.
2. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science 1995;269:1875-7.
3. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000;19:2523-31.
4. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984;37:1035-42.
5. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al. Transformation of hematopoietic cells by BCR/ ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997;16:6151-61.
6. Chen JL, Limnander A, Rothman PB. Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 2008;111:1677-85.
7. Guo G, Qiu X, Wang S, Chen Y, Rothman PB, Wang Z, et al. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene 2010;29:3845-53.
8. Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, et al. TargetingPIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fmslike tyrosine kinase 3 and BCR/ABL. Cancer Res 2006;66:3828-35.
9. Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 2002;99:4531-9.
10. Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 2012;119: 3550-60.
11. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011;11:23-34.
12. Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, Gapter L, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001;2: 167-79.
13. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, et al. Pim-1 is upregulated by constitutively activated FLT3 and plays a role in FLT3- mediated cell survival. Blood 2005;105:1759-67.
14. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-6.
15. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005;3:443-51.
16. Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 2010;29:2477-87.
17. Peng C, Knebel A, Morrice NA, Li X, Barringer K, Li J, et al. Pim kinase substrate identification and specificity. J Biochem 2007;141:353-62.
18. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999;274:18659-66.
19. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004;279: 48319-28.
20. Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 2004;103:3744-50.
21. Bullock AN, Debreczeni J, Amos AL, Knapp S, Turk BE. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 2005;280: 41675-82.
22. Kim HR, Oh BC, Choi JK, Bae SC. Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J Cell Biochem 2008;105:1048-58.
23. Morishita D, Takami M, Yoshikawa S, Katayama R, Sato S, Kukimoto- Niino M, et al. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. J Biol Chem 2011;286:2681-8.
24. Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N. eIF4B controls survival and proliferation and is regulated by protooncogenic signaling pathways. Cell Cycle 2010;9:4106-9.
25. Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25:1182-8.
26. Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011;208: 1799-807.
27. Schatz JH, Wendel HG. Targeted cancer therapy: what if the driver is just a messenger? Cell Cycle 2011;10:3830-3.
28. Nielsen KH, Behrens MA, He Y, Oliveira CL, Jensen LS, Hoffmann SV, et al. Synergistic activation of eIF4A by eIF4B and eIF4G. Nucleic Acids Res 2011;39:2678-89.
29. Raught B, Gingras AC, Gygi SP, Imataka H, Morino S, Gradi A, et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J 2000;19:434-44.
30. van Gorp AGM, Vos KED, Brenkman AB, Bremer A, van den Broek N, Zwartkruis F, et al. AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 2009;28:95-106.
31. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 2006;25:2781-91.
32. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011; 13:132-41.
33. Hernandez G, Vazquez-Pianzola P, Zurbriggen A, Altmann M, Sierra JM, Rivera-Pomar R. Two functionally redundant isoforms of Drosophila melanogaster eukaryotic initiation factor 4B are involved in cap-dependent translation, cell survival, and proliferation. Eur J Biochem 2004;271:2923-36.
34. Limnander A, Danial NN, Rothman PB. v-Abl signaling disrupts SOCS- 1 function in transformed pre-B cells. Mol Cell 2004;15:329-41.
35. Qiu X, Guo G, Chen K, Kashiwada M, Druker BJ, Rothman PB, et al. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Ablinduced tumorigenesis. Neoplasia 2012;14:547-58.
36. WangS, Li H, Chen Y, Wei H, Gao GF, Liu H, et al. Transport of influenza virus neuraminidase (NA) to host cell surface is regulated by ARHGAP21 and Cdc42 proteins. J Biol Chem 2012;287:9804-16.
37. van der LugtNM, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J, et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995;14:2536-44.
38. Lu D, Ma Y, Zhang W, Bao D, Dong W, Lian H, et al. Knockdown of cytochrome P450 2E1 inhibits oxidative stress and apoptosis in the cTnT(R141W) dilated cardiomyopathy transgenic mice. Hypertension 2012;60:81-9.
39. Chen XP, Losman JA, Cowan S, Donahue E, Fay S, Vuong BQ, et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci U S A 2002;99:2175-80.
40. Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF, et al. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 2010;30:1478-85.
41. Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z, et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010;115: 824-33.
42. Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, et al. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 2011;147:306-19.
43. Limnander A, Rothman PB. Abl oncogene bypasses normal regulation of Jak/STAT activation. Cell Cycle 2004;3:1486-8.
44. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008;22:686-707.
45. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2013;32:2601-13.
46. Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011;118:693-702.
47. Deutsch AJ, Aigelsreiter A, Staber PB, BehamA, Linkesch W, Guelly C, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood 2007;109: 3500-4.
48. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003;17:1841-54.
49. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A 1995;92: 5287-91.
50. Banerjee A, Rothman P. IL-7 reconstitutes multiple aspects of v-Ablmediated signaling. J Immunol 1998;161:4611-7.